Onsdag 28 Oktober | 20:04:20 Europe / Stockholm

All ägardata du vill ha finns i Holdings!

Annexin Pharmaceuticals - RVO data on the horizon

2023-06-02 15:08:00

Redeye reviews the case of Annexin in the wake of the company’s Q1 report and recent newsflow. We conclude that 2023 will be an eventful year for the company, with initial phase II data in RVO potentially this summer.

Read more and download the Research Update.

Follow companies at Redeye to receive the latest equity research within Life Science and Technology.

This is a press release from Redeye - Research Powered Investment Banking. www.redeye.se/